Valuation: Arcus Biosciences, Inc.

Market Cap 3.52B 3.08B 2.84B 2.61B 4.95B 339B 5.04B 33.93B 13.31B 166B 13.23B 12.94B 571B P/E 2026 *
-7.62x
P/E 2027 * -8.31x
Enterprise Value 2.9B 2.54B 2.34B 2.15B 4.08B 279B 4.15B 27.95B 10.97B 137B 10.9B 10.66B 471B EV / Sales 2026 *
34.1x
EV / Sales 2027 * 35.1x
Free-Float
70.85%
Yield 2026 *
-
Yield 2027 * -
1 day-1.09%
1 week-7.40%
Current month-9.11%
1 month+15.88%
3 months+18.23%
6 months+28.59%
Current year+17.58%
1 week 27.21
Extreme 27.21
29.79
1 month 23.6
Extreme 23.6
31.74
Current year 18.52
Extreme 18.515
31.74
1 year 8.84
Extreme 8.84
31.74
3 years 6.5
Extreme 6.5
31.74
5 years 6.5
Extreme 6.5
49.1
10 years 6.3
Extreme 6.3
49.1
Manager TitleAgeSince
President 68 01/05/2015
Chief Executive Officer 67 01/05/2015
Director of Finance/CFO 53 01/08/2020
Director TitleAgeSince
Chairman 67 01/12/2017
Director/Board Member 65 18/09/2017
Director/Board Member 71 01/05/2015
Date Insider Type Main position Quantity % Market Cap.
07-10Sell

Founder

-20,067 0.0160%
06-24Sell

Founder

-6,431 0.0051%
06-11Free

Director

22,600 0.0180%
Change 5-day change 1-year change 3-year change Capi.($)
-1.09%-7.40%+210.30%+27.95% 3.52B
-0.17%+1.47%+3.16%+6.80% 50.35B
-0.29%-2.81%+387.81%+591.82% 39.21B
-0.49%+1.48%+31.16%-6.46% 34.52B
+1.53%+3.11%+15.41%+58.54% 34.6B
+1.68%-0.62%+3.30%+27.34% 27.05B
+1.13%-3.11% - - 16.68B
-1.29%-0.52%+69.24%+117.60% 15.11B
+0.43%+3.34%+14.96%+17.46% 13.85B
+2.45%+3.99%+18.20%-30.12% 13.18B
Average +0.39%+0.11%+83.73%+90.10% 24.81B
Weighted average by Cap. +0.38%+0.71%+83.40%+120.19%

Financials

2026 *2027 *
Net sales 85.06M 74.37M 68.6M 63.06M 119M 8.18B 122M 819M 321M 4B 319M 312M 13.79B 93.06M 81.36M 75.05M 68.99M 131M 8.95B 133M 896M 352M 4.38B 349M 342M 15.08B
Net income -456M -399M -368M -338M -641M -43.91B -652M -4.39B -1.72B -21.46B -1.71B -1.68B -73.98B -431M -376M -347M -319M -605M -41.43B -615M -4.15B -1.63B -20.25B -1.62B -1.58B -69.79B
Net Debt -621M -543M -501M -461M -873M -59.79B -888M -5.98B -2.35B -29.22B -2.33B -2.28B -101B -259M -227M -209M -192M -364M -24.95B -371M -2.5B -980M -12.2B -974M -953M -42.04B
Logo Arcus Biosciences, Inc.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Employees
601
Date Price Change Volume
15/07/26 US$28.02 -1.09% 718,651
14/07/26 US$28.33 +0.93% 801,993
13/07/26 US$28.07 -2.94% 954,774
10/07/26 US$28.92 -3.47% 811,732
09/07/26 US$29.96 -0.99% 753,380
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
28.02USD
Average target price
35.75USD
Spread / Average Target
+27.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RCUS Stock